Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 92 | 2024 | 13576 | 6.300 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 64 | 2024 | 5422 | 6.020 |
Why?
|
Pneumonia | 21 | 2023 | 2162 | 4.700 |
Why?
|
Lung Diseases, Interstitial | 30 | 2024 | 945 | 3.440 |
Why?
|
Tomography, X-Ray Computed | 83 | 2024 | 20766 | 2.430 |
Why?
|
Tumor Burden | 15 | 2023 | 1913 | 2.250 |
Why?
|
Diagnostic Imaging | 14 | 2024 | 3541 | 2.020 |
Why?
|
Protein Kinase Inhibitors | 22 | 2022 | 5707 | 1.970 |
Why?
|
Solitary Pulmonary Nodule | 5 | 2023 | 281 | 1.880 |
Why?
|
Antineoplastic Agents | 21 | 2023 | 13696 | 1.700 |
Why?
|
Lung | 47 | 2024 | 10087 | 1.590 |
Why?
|
Radiology | 11 | 2024 | 2117 | 1.510 |
Why?
|
Awards and Prizes | 3 | 2020 | 365 | 1.460 |
Why?
|
Lung Diseases | 12 | 2023 | 1925 | 1.410 |
Why?
|
Thymus Hyperplasia | 3 | 2015 | 32 | 1.390 |
Why?
|
Exhalation | 9 | 2019 | 185 | 1.380 |
Why?
|
Immunotherapy | 18 | 2021 | 4740 | 1.250 |
Why?
|
Thymus Neoplasms | 4 | 2018 | 277 | 1.230 |
Why?
|
Thoracic Neoplasms | 3 | 2021 | 269 | 1.190 |
Why?
|
Quinazolines | 5 | 2016 | 1374 | 1.180 |
Why?
|
Antibodies, Monoclonal | 12 | 2018 | 9261 | 1.160 |
Why?
|
Neoplasms | 24 | 2023 | 22389 | 1.080 |
Why?
|
Thorax | 4 | 2023 | 559 | 1.050 |
Why?
|
Radiography, Thoracic | 12 | 2020 | 1320 | 1.030 |
Why?
|
Pseudolymphoma | 2 | 2015 | 30 | 0.940 |
Why?
|
Sarcoidosis, Pulmonary | 2 | 2018 | 45 | 0.910 |
Why?
|
Radiographic Image Enhancement | 7 | 2014 | 877 | 0.910 |
Why?
|
Humans | 228 | 2024 | 768298 | 0.830 |
Why?
|
Melanoma | 10 | 2019 | 5705 | 0.820 |
Why?
|
Alveolitis, Extrinsic Allergic | 2 | 2021 | 62 | 0.800 |
Why?
|
Thoracic Diseases | 2 | 2017 | 99 | 0.780 |
Why?
|
Idiopathic Pulmonary Fibrosis | 7 | 2023 | 520 | 0.770 |
Why?
|
Neuroendocrine Tumors | 3 | 2018 | 657 | 0.770 |
Why?
|
Granuloma | 3 | 2018 | 329 | 0.770 |
Why?
|
Multiple Pulmonary Nodules | 2 | 2020 | 174 | 0.750 |
Why?
|
Aged, 80 and over | 66 | 2023 | 59683 | 0.740 |
Why?
|
Aged | 108 | 2024 | 171544 | 0.740 |
Why?
|
Molecular Targeted Therapy | 10 | 2021 | 2830 | 0.710 |
Why?
|
Radiation Pneumonitis | 2 | 2020 | 100 | 0.700 |
Why?
|
Radiography | 9 | 2024 | 6993 | 0.690 |
Why?
|
Middle Aged | 111 | 2024 | 223463 | 0.670 |
Why?
|
Mutation | 32 | 2023 | 30230 | 0.670 |
Why?
|
Immunoconjugates | 3 | 2023 | 969 | 0.650 |
Why?
|
Pulmonary Embolism | 8 | 2023 | 2587 | 0.640 |
Why?
|
Disease Progression | 18 | 2024 | 13646 | 0.610 |
Why?
|
Male | 121 | 2024 | 364870 | 0.590 |
Why?
|
Thymus Gland | 3 | 2015 | 1266 | 0.580 |
Why?
|
Female | 130 | 2024 | 397050 | 0.580 |
Why?
|
Bronchiectasis | 3 | 2022 | 139 | 0.570 |
Why?
|
Diaphragm | 5 | 2019 | 359 | 0.570 |
Why?
|
Lymphoma | 2 | 2016 | 1907 | 0.560 |
Why?
|
Image Processing, Computer-Assisted | 13 | 2015 | 9063 | 0.540 |
Why?
|
Periodicals as Topic | 4 | 2020 | 1469 | 0.530 |
Why?
|
Adenocarcinoma | 4 | 2020 | 6404 | 0.520 |
Why?
|
Tomography, Spiral Computed | 4 | 2005 | 274 | 0.510 |
Why?
|
Adult | 85 | 2023 | 223622 | 0.500 |
Why?
|
Pulmonary Emphysema | 6 | 2021 | 690 | 0.490 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7453 | 0.490 |
Why?
|
Gene Rearrangement | 2 | 2016 | 1139 | 0.470 |
Why?
|
Ovarian Diseases | 3 | 2006 | 137 | 0.470 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2020 | 567 | 0.470 |
Why?
|
Mediastinal Cyst | 1 | 2014 | 30 | 0.460 |
Why?
|
Retrospective Studies | 50 | 2024 | 81768 | 0.460 |
Why?
|
Carcinoma, Renal Cell | 6 | 2018 | 3199 | 0.460 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 5 | 2024 | 1226 | 0.450 |
Why?
|
Lung Transplantation | 1 | 2023 | 1309 | 0.430 |
Why?
|
Internship and Residency | 5 | 2019 | 5948 | 0.430 |
Why?
|
Respiratory Function Tests | 10 | 2019 | 1696 | 0.410 |
Why?
|
Exons | 5 | 2020 | 2392 | 0.410 |
Why?
|
Mucin-5B | 6 | 2023 | 148 | 0.400 |
Why?
|
Neoplasm Staging | 12 | 2021 | 11254 | 0.390 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2016 | 489 | 0.390 |
Why?
|
Treatment Outcome | 32 | 2023 | 65365 | 0.390 |
Why?
|
Arthritis, Rheumatoid | 7 | 2024 | 3776 | 0.390 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2023 | 1765 | 0.390 |
Why?
|
Genomics | 11 | 2024 | 5916 | 0.390 |
Why?
|
Emphysema | 2 | 2021 | 237 | 0.380 |
Why?
|
Positron-Emission Tomography | 5 | 2015 | 6670 | 0.370 |
Why?
|
Angiogenesis Inhibitors | 5 | 2015 | 2060 | 0.370 |
Why?
|
Pleural Neoplasms | 1 | 2016 | 612 | 0.370 |
Why?
|
Pregnancy, Ectopic | 2 | 2003 | 146 | 0.370 |
Why?
|
Japan | 4 | 2019 | 1418 | 0.370 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2020 | 5335 | 0.360 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 10 | 2024 | 3242 | 0.360 |
Why?
|
Pyridines | 3 | 2017 | 2889 | 0.350 |
Why?
|
NF-E2-Related Factor 2 | 5 | 2024 | 378 | 0.340 |
Why?
|
Disease-Free Survival | 6 | 2019 | 6856 | 0.340 |
Why?
|
Pyrazoles | 3 | 2017 | 2021 | 0.340 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2924 | 0.340 |
Why?
|
Survival Rate | 10 | 2023 | 12870 | 0.340 |
Why?
|
Hemosiderosis | 1 | 2010 | 66 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11854 | 0.330 |
Why?
|
Respiration | 5 | 2019 | 1667 | 0.330 |
Why?
|
Leiomyoma | 2 | 2005 | 644 | 0.320 |
Why?
|
Peristalsis | 2 | 2006 | 60 | 0.310 |
Why?
|
Medical Oncology | 3 | 2021 | 2348 | 0.310 |
Why?
|
Sirolimus | 1 | 2015 | 1542 | 0.300 |
Why?
|
Tomography Scanners, X-Ray Computed | 2 | 2006 | 172 | 0.300 |
Why?
|
Uterine Contraction | 2 | 2006 | 91 | 0.290 |
Why?
|
Bronchial Diseases | 2 | 2006 | 151 | 0.290 |
Why?
|
Inhalation | 2 | 2005 | 145 | 0.290 |
Why?
|
Pulmonary Fibrosis | 4 | 2021 | 506 | 0.280 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2411 | 0.280 |
Why?
|
Observer Variation | 5 | 2020 | 2623 | 0.270 |
Why?
|
Smoking | 9 | 2024 | 9109 | 0.270 |
Why?
|
Pleura | 2 | 2019 | 248 | 0.270 |
Why?
|
Iohexol | 3 | 2014 | 205 | 0.270 |
Why?
|
Gene Amplification | 2 | 2023 | 1090 | 0.270 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2010 | 459 | 0.270 |
Why?
|
Statistics, Nonparametric | 5 | 2013 | 2862 | 0.270 |
Why?
|
Incidence | 10 | 2023 | 21544 | 0.260 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1076 | 0.260 |
Why?
|
Sarcoidosis | 2 | 2017 | 534 | 0.260 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2015 | 1077 | 0.260 |
Why?
|
Cohort Studies | 21 | 2022 | 41791 | 0.260 |
Why?
|
Computers, Handheld | 2 | 2004 | 211 | 0.250 |
Why?
|
Nuclear Proteins | 6 | 2023 | 5802 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9433 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 6541 | 0.250 |
Why?
|
Prognosis | 14 | 2020 | 30020 | 0.240 |
Why?
|
Uterine Neoplasms | 2 | 2005 | 1426 | 0.240 |
Why?
|
Kidney Neoplasms | 5 | 2018 | 4301 | 0.240 |
Why?
|
Hemorrhage | 4 | 2017 | 3461 | 0.240 |
Why?
|
Reproducibility of Results | 11 | 2019 | 20224 | 0.240 |
Why?
|
Magnetic Resonance Imaging | 10 | 2018 | 36849 | 0.230 |
Why?
|
Liver Neoplasms | 3 | 2017 | 4360 | 0.230 |
Why?
|
Artifacts | 5 | 2006 | 1930 | 0.230 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2019 | 4069 | 0.230 |
Why?
|
Forced Expiratory Volume | 4 | 2019 | 1820 | 0.230 |
Why?
|
Molecular Imaging | 1 | 2011 | 827 | 0.220 |
Why?
|
Image Enhancement | 2 | 2013 | 2894 | 0.220 |
Why?
|
Contrast Media | 8 | 2014 | 5337 | 0.220 |
Why?
|
Magnetic Resonance Imaging, Cine | 3 | 2006 | 1092 | 0.220 |
Why?
|
Hemangioendothelioma | 1 | 2004 | 112 | 0.220 |
Why?
|
Adnexal Diseases | 1 | 2004 | 105 | 0.220 |
Why?
|
DNA Helicases | 3 | 2023 | 853 | 0.220 |
Why?
|
Camptothecin | 2 | 2023 | 593 | 0.210 |
Why?
|
Pelvic Inflammatory Disease | 1 | 2003 | 96 | 0.210 |
Why?
|
Brain Neoplasms | 4 | 2023 | 9197 | 0.210 |
Why?
|
Bronchi | 2 | 2006 | 847 | 0.210 |
Why?
|
Computer Communication Networks | 1 | 2004 | 295 | 0.210 |
Why?
|
Diagnosis, Differential | 8 | 2014 | 13019 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
Vascular Neoplasms | 1 | 2004 | 167 | 0.200 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2018 | 640 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3722 | 0.200 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2015 | 3111 | 0.190 |
Why?
|
Glioblastoma | 1 | 2016 | 3526 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2015 | 1536 | 0.180 |
Why?
|
Republic of Korea | 1 | 2023 | 587 | 0.180 |
Why?
|
Prevalence | 8 | 2024 | 15868 | 0.180 |
Why?
|
Respiratory System Abnormalities | 1 | 2021 | 67 | 0.180 |
Why?
|
Drug Monitoring | 2 | 2018 | 964 | 0.180 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2020 | 3666 | 0.180 |
Why?
|
Fatty Liver | 2 | 2005 | 807 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8750 | 0.170 |
Why?
|
Infectious Disease Medicine | 1 | 2020 | 49 | 0.170 |
Why?
|
Phospholipase D | 1 | 2019 | 67 | 0.170 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2015 | 3520 | 0.160 |
Why?
|
Iceland | 4 | 2020 | 183 | 0.160 |
Why?
|
Genes, cdc | 1 | 2019 | 114 | 0.160 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2003 | 335 | 0.160 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2016 | 1628 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 1890 | 0.160 |
Why?
|
Portugal | 1 | 2018 | 91 | 0.160 |
Why?
|
Histiocytosis | 1 | 2018 | 39 | 0.160 |
Why?
|
Gastrointestinal Tract | 1 | 2005 | 839 | 0.160 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2024 | 3411 | 0.150 |
Why?
|
Biliary Tract Diseases | 1 | 2019 | 158 | 0.150 |
Why?
|
Posture | 3 | 2017 | 956 | 0.150 |
Why?
|
Tamoxifen | 1 | 2003 | 968 | 0.150 |
Why?
|
Matrix Metalloproteinase 7 | 2 | 2015 | 60 | 0.150 |
Why?
|
Tidal Volume | 2 | 2019 | 515 | 0.150 |
Why?
|
Pulmonary Medicine | 1 | 2020 | 223 | 0.150 |
Why?
|
Total Lung Capacity | 3 | 2015 | 149 | 0.150 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2018 | 2058 | 0.150 |
Why?
|
Thailand | 1 | 2018 | 288 | 0.150 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 264 | 0.150 |
Why?
|
Risk Factors | 12 | 2023 | 74954 | 0.150 |
Why?
|
Benzeneacetamides | 1 | 2017 | 36 | 0.140 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39405 | 0.140 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5857 | 0.140 |
Why?
|
Patient Care Management | 1 | 2021 | 304 | 0.140 |
Why?
|
Cell Proliferation | 1 | 2013 | 10464 | 0.140 |
Why?
|
Professional Competence | 1 | 2020 | 430 | 0.140 |
Why?
|
Survival Analysis | 5 | 2021 | 10117 | 0.140 |
Why?
|
North America | 1 | 2020 | 1290 | 0.140 |
Why?
|
Polymorphism, Genetic | 3 | 2017 | 4250 | 0.140 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8562 | 0.140 |
Why?
|
Retreatment | 1 | 2018 | 600 | 0.130 |
Why?
|
Oximes | 1 | 2018 | 303 | 0.130 |
Why?
|
Movement | 3 | 2019 | 1490 | 0.130 |
Why?
|
Antirheumatic Agents | 2 | 2023 | 1378 | 0.130 |
Why?
|
Mammography | 2 | 2005 | 2434 | 0.130 |
Why?
|
Pleural Diseases | 1 | 2017 | 138 | 0.130 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 2884 | 0.130 |
Why?
|
Young Adult | 13 | 2023 | 60048 | 0.130 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2018 | 2524 | 0.130 |
Why?
|
Pyrimidinones | 1 | 2018 | 386 | 0.120 |
Why?
|
Asbestos | 1 | 2017 | 251 | 0.120 |
Why?
|
Receptor, trkA | 1 | 2016 | 159 | 0.120 |
Why?
|
Causality | 1 | 2021 | 1255 | 0.120 |
Why?
|
Hormone Antagonists | 1 | 2015 | 107 | 0.120 |
Why?
|
Internationality | 1 | 2020 | 1008 | 0.120 |
Why?
|
Thyroiditis | 1 | 2015 | 86 | 0.120 |
Why?
|
Prednisolone | 1 | 2016 | 327 | 0.120 |
Why?
|
Prednisone | 1 | 2019 | 1568 | 0.120 |
Why?
|
Galectin 3 | 1 | 2016 | 240 | 0.120 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 937 | 0.120 |
Why?
|
Lung Volume Measurements | 2 | 2006 | 382 | 0.110 |
Why?
|
Imaging, Three-Dimensional | 5 | 2010 | 4076 | 0.110 |
Why?
|
Spirometry | 4 | 2021 | 928 | 0.110 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 450 | 0.110 |
Why?
|
Remission Induction | 2 | 2019 | 2407 | 0.110 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 720 | 0.110 |
Why?
|
Lymphocytes | 1 | 2021 | 2610 | 0.110 |
Why?
|
Forecasting | 1 | 2023 | 2948 | 0.110 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4921 | 0.110 |
Why?
|
Chemokine CXCL10 | 1 | 2015 | 311 | 0.110 |
Why?
|
Lymphatic Diseases | 1 | 2015 | 319 | 0.110 |
Why?
|
Hepatitis | 1 | 2015 | 227 | 0.110 |
Why?
|
Vital Capacity | 3 | 2024 | 984 | 0.110 |
Why?
|
Intestinal Neoplasms | 1 | 2016 | 316 | 0.110 |
Why?
|
Receptor, erbB-2 | 1 | 2023 | 2588 | 0.110 |
Why?
|
Carcinoid Tumor | 1 | 2014 | 223 | 0.100 |
Why?
|
Ovarian Neoplasms | 2 | 2015 | 4908 | 0.100 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 14736 | 0.100 |
Why?
|
Pyridones | 1 | 2018 | 818 | 0.100 |
Why?
|
Thymoma | 1 | 2014 | 191 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2019 | 2056 | 0.100 |
Why?
|
DNA Mutational Analysis | 3 | 2020 | 4120 | 0.100 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 12557 | 0.100 |
Why?
|
Radiotherapy | 1 | 2019 | 1509 | 0.100 |
Why?
|
Promoter Regions, Genetic | 3 | 2019 | 5800 | 0.100 |
Why?
|
Imidazoles | 1 | 2018 | 1168 | 0.100 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2013 | 101 | 0.100 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2565 | 0.090 |
Why?
|
Severity of Illness Index | 5 | 2020 | 15939 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2950 | 0.090 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3236 | 0.090 |
Why?
|
Transcription Factors | 4 | 2023 | 12166 | 0.090 |
Why?
|
Hormones | 1 | 2015 | 870 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2015 | 718 | 0.090 |
Why?
|
Venous Thromboembolism | 2 | 2016 | 1881 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2003 | 3334 | 0.090 |
Why?
|
Radiodermatitis | 1 | 2010 | 61 | 0.090 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 1207 | 0.090 |
Why?
|
Organ Specificity | 1 | 2015 | 1966 | 0.090 |
Why?
|
Cysts | 1 | 2015 | 685 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3212 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1598 | 0.090 |
Why?
|
Mutagenesis, Insertional | 1 | 2013 | 662 | 0.090 |
Why?
|
Pectoralis Muscles | 1 | 2010 | 86 | 0.090 |
Why?
|
Mutation, Missense | 2 | 2023 | 2593 | 0.080 |
Why?
|
Pathology, Molecular | 1 | 2013 | 329 | 0.080 |
Why?
|
Terminology as Topic | 2 | 2015 | 1539 | 0.080 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2010 | 234 | 0.080 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2015 | 617 | 0.080 |
Why?
|
Age Factors | 8 | 2021 | 18472 | 0.080 |
Why?
|
Disease Models, Animal | 4 | 2018 | 18358 | 0.080 |
Why?
|
Prospective Studies | 12 | 2023 | 54921 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3431 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1262 | 0.080 |
Why?
|
Withholding Treatment | 1 | 2013 | 620 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 8051 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3785 | 0.080 |
Why?
|
Taxoids | 1 | 2012 | 668 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2019 | 2734 | 0.080 |
Why?
|
Pancreatitis | 1 | 2015 | 1087 | 0.080 |
Why?
|
Feasibility Studies | 4 | 2019 | 5311 | 0.070 |
Why?
|
Recurrence | 3 | 2020 | 8501 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2012 | 683 | 0.070 |
Why?
|
Breast Neoplasms | 3 | 2005 | 21163 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12092 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2536 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2015 | 1042 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11117 | 0.070 |
Why?
|
Telomere | 2 | 2024 | 943 | 0.070 |
Why?
|
Pancreatic Neoplasms | 2 | 2016 | 5443 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2012 | 864 | 0.070 |
Why?
|
Fetal Organ Maturity | 1 | 2006 | 83 | 0.070 |
Why?
|
Colitis | 1 | 2015 | 1244 | 0.070 |
Why?
|
Inflammasomes | 1 | 2012 | 540 | 0.070 |
Why?
|
Genome-Wide Association Study | 2 | 2023 | 12775 | 0.070 |
Why?
|
Exercise Tolerance | 1 | 2012 | 848 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2016 | 2433 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 2 | 2016 | 4526 | 0.070 |
Why?
|
Ovarian Cysts | 1 | 2006 | 108 | 0.060 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2010 | 646 | 0.060 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2013 | 959 | 0.060 |
Why?
|
Algorithms | 1 | 2006 | 14154 | 0.060 |
Why?
|
Vascular Diseases | 1 | 2014 | 1161 | 0.060 |
Why?
|
Serous Membrane | 1 | 2005 | 23 | 0.060 |
Why?
|
Respiration, Artificial | 1 | 2017 | 2721 | 0.060 |
Why?
|
Logistic Models | 5 | 2019 | 13323 | 0.060 |
Why?
|
Cause of Death | 1 | 2016 | 3728 | 0.060 |
Why?
|
Liver Diseases | 1 | 2014 | 1301 | 0.060 |
Why?
|
Stomach Neoplasms | 1 | 2015 | 1481 | 0.060 |
Why?
|
Longitudinal Studies | 5 | 2021 | 14783 | 0.060 |
Why?
|
Mice | 8 | 2023 | 82004 | 0.060 |
Why?
|
Aging | 2 | 2021 | 8764 | 0.060 |
Why?
|
Tracheal Diseases | 1 | 2005 | 118 | 0.060 |
Why?
|
Myometrium | 1 | 2005 | 174 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3643 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10266 | 0.060 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6084 | 0.060 |
Why?
|
Ligands | 2 | 2021 | 3283 | 0.060 |
Why?
|
ROC Curve | 3 | 2017 | 3622 | 0.050 |
Why?
|
Syndrome | 1 | 2010 | 3275 | 0.050 |
Why?
|
Cartilage Diseases | 1 | 2005 | 159 | 0.050 |
Why?
|
Ifosfamide | 1 | 2023 | 234 | 0.050 |
Why?
|
Thrombosis | 1 | 2017 | 2955 | 0.050 |
Why?
|
Angiography | 2 | 2006 | 1597 | 0.050 |
Why?
|
Torsion Abnormality | 1 | 2003 | 92 | 0.050 |
Why?
|
Outpatients | 1 | 2011 | 1603 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2021 | 15455 | 0.050 |
Why?
|
Ascites | 1 | 2004 | 338 | 0.050 |
Why?
|
Retroperitoneal Space | 1 | 2003 | 173 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2005 | 3438 | 0.050 |
Why?
|
Traction | 1 | 2022 | 111 | 0.050 |
Why?
|
Endometrium | 1 | 2005 | 407 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2017 | 4528 | 0.050 |
Why?
|
Celiac Disease | 1 | 2010 | 820 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2023 | 18047 | 0.050 |
Why?
|
Rupture | 1 | 2003 | 444 | 0.050 |
Why?
|
Computer-Assisted Instruction | 1 | 2005 | 364 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2023 | 228 | 0.050 |
Why?
|
Mucous Membrane | 1 | 2005 | 659 | 0.050 |
Why?
|
Linear Models | 3 | 2019 | 5878 | 0.050 |
Why?
|
United States | 4 | 2020 | 73144 | 0.050 |
Why?
|
Models, Biological | 2 | 2018 | 9494 | 0.050 |
Why?
|
Fallopian Tubes | 1 | 2002 | 179 | 0.050 |
Why?
|
Gadolinium DTPA | 1 | 2004 | 823 | 0.050 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2022 | 331 | 0.050 |
Why?
|
Respiratory Mechanics | 1 | 2005 | 722 | 0.050 |
Why?
|
Sucrose | 1 | 2021 | 159 | 0.040 |
Why?
|
Anticoagulants | 2 | 2016 | 4842 | 0.040 |
Why?
|
Ultrasonography | 1 | 2014 | 6001 | 0.040 |
Why?
|
TATA Box Binding Protein-Like Proteins | 1 | 2019 | 9 | 0.040 |
Why?
|
Chromosomes | 1 | 2023 | 579 | 0.040 |
Why?
|
Pericardium | 1 | 2004 | 679 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2240 | 0.040 |
Why?
|
beta Karyopherins | 1 | 2019 | 46 | 0.040 |
Why?
|
Airway Obstruction | 1 | 2005 | 672 | 0.040 |
Why?
|
Boston | 2 | 2024 | 9371 | 0.040 |
Why?
|
Radiology Information Systems | 1 | 2004 | 533 | 0.040 |
Why?
|
Statistics as Topic | 1 | 2006 | 2363 | 0.040 |
Why?
|
Chorionic Gonadotropin | 1 | 2002 | 458 | 0.040 |
Why?
|
Animals | 8 | 2023 | 169322 | 0.040 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2021 | 199 | 0.040 |
Why?
|
Aneuploidy | 1 | 2023 | 572 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3616 | 0.040 |
Why?
|
Probability | 1 | 2024 | 2482 | 0.040 |
Why?
|
Immunophenotyping | 1 | 2024 | 1866 | 0.040 |
Why?
|
Fetus | 1 | 2006 | 1883 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2012 | 4940 | 0.040 |
Why?
|
Models, Statistical | 1 | 2013 | 5099 | 0.040 |
Why?
|
Endometriosis | 1 | 2006 | 875 | 0.040 |
Why?
|
Biopsy | 1 | 2010 | 6808 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2015 | 6969 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3811 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2020 | 22292 | 0.040 |
Why?
|
Regression Analysis | 3 | 2015 | 6350 | 0.040 |
Why?
|
Organizational Objectives | 1 | 2019 | 426 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7458 | 0.040 |
Why?
|
Risk Adjustment | 1 | 2021 | 603 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3252 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2003 | 1070 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2023 | 1780 | 0.030 |
Why?
|
Odds Ratio | 2 | 2021 | 9681 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2018 | 17132 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15652 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2018 | 330 | 0.030 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 936 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2003 | 1094 | 0.030 |
Why?
|
Genotype | 3 | 2017 | 13038 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1195 | 0.030 |
Why?
|
X-Rays | 1 | 2016 | 312 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 541 | 0.030 |
Why?
|
Fever | 1 | 2003 | 1620 | 0.030 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 1 | 2015 | 49 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2016 | 540 | 0.030 |
Why?
|
Bronchography | 2 | 2005 | 74 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1622 | 0.030 |
Why?
|
Pulmonary Artery | 1 | 2023 | 1945 | 0.030 |
Why?
|
Breast | 1 | 2003 | 1975 | 0.030 |
Why?
|
Urologic Neoplasms | 1 | 2018 | 319 | 0.030 |
Why?
|
Incidental Findings | 1 | 2019 | 697 | 0.030 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2016 | 344 | 0.030 |
Why?
|
Immune System | 1 | 2019 | 801 | 0.030 |
Why?
|
Apoptosis | 2 | 2020 | 9506 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2015 | 642 | 0.030 |
Why?
|
Vitamin K | 1 | 2016 | 314 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2005 | 2542 | 0.030 |
Why?
|
Motion | 1 | 2016 | 789 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8628 | 0.030 |
Why?
|
Pregnancy | 3 | 2006 | 30198 | 0.030 |
Why?
|
Methotrexate | 1 | 2019 | 1722 | 0.030 |
Why?
|
Equipment Design | 1 | 2020 | 3529 | 0.030 |
Why?
|
Internet | 1 | 2005 | 3107 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2015 | 590 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2023 | 3457 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2015 | 552 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 892 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2003 | 1946 | 0.020 |
Why?
|
Codon | 1 | 2013 | 599 | 0.020 |
Why?
|
Problem Solving | 1 | 2014 | 443 | 0.020 |
Why?
|
Registries | 2 | 2019 | 8378 | 0.020 |
Why?
|
Sex Factors | 2 | 2015 | 10656 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1642 | 0.020 |
Why?
|
Caspase 1 | 1 | 2012 | 226 | 0.020 |
Why?
|
Chemokines | 1 | 2015 | 962 | 0.020 |
Why?
|
Bleomycin | 1 | 2012 | 493 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3060 | 0.020 |
Why?
|
DNA Repair | 1 | 2020 | 2050 | 0.020 |
Why?
|
Small Molecule Libraries | 1 | 2016 | 743 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1891 | 0.020 |
Why?
|
Genetic Loci | 1 | 2019 | 2630 | 0.020 |
Why?
|
DNA Damage | 1 | 2020 | 2459 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3940 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2168 | 0.020 |
Why?
|
Genes, p53 | 1 | 2012 | 715 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2046 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 636 | 0.020 |
Why?
|
Hydrocortisone | 1 | 2017 | 1841 | 0.020 |
Why?
|
Life Style | 1 | 2020 | 3930 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2664 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2013 | 2750 | 0.020 |
Why?
|
China | 1 | 2015 | 2389 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2012 | 598 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4774 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1760 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 13050 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4265 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3960 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4859 | 0.020 |
Why?
|
Liver | 1 | 2003 | 7570 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2012 | 1339 | 0.020 |
Why?
|
ras Proteins | 1 | 2012 | 1058 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2015 | 930 | 0.020 |
Why?
|
Autoantibodies | 1 | 2015 | 2126 | 0.020 |
Why?
|
Necrosis | 1 | 2010 | 1619 | 0.020 |
Why?
|
Models, Molecular | 1 | 2016 | 5408 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 2015 | 1166 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2010 | 887 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2708 | 0.020 |
Why?
|
Floxuridine | 1 | 2005 | 44 | 0.020 |
Why?
|
Tegafur | 1 | 2005 | 39 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2010 | 1627 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2015 | 6512 | 0.020 |
Why?
|
Iopamidol | 1 | 2005 | 187 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8326 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2012 | 1492 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2015 | 2661 | 0.010 |
Why?
|
Programming Languages | 1 | 2005 | 130 | 0.010 |
Why?
|
Walking | 1 | 2012 | 1201 | 0.010 |
Why?
|
Venules | 1 | 2004 | 161 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23629 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7443 | 0.010 |
Why?
|
Exercise Test | 1 | 2012 | 2186 | 0.010 |
Why?
|
Biomedical Research | 1 | 2019 | 3464 | 0.010 |
Why?
|
Uracil | 1 | 2005 | 210 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8902 | 0.010 |
Why?
|
Sarcoma | 1 | 2015 | 1806 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6209 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2015 | 2909 | 0.010 |
Why?
|
Menstrual Cycle | 1 | 2006 | 545 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 3609 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 2010 | 1386 | 0.010 |
Why?
|
Uterus | 1 | 2006 | 661 | 0.010 |
Why?
|
Endosonography | 1 | 2006 | 622 | 0.010 |
Why?
|
Systems Integration | 1 | 2004 | 430 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2015 | 2331 | 0.010 |
Why?
|
Adolescent | 3 | 2023 | 89182 | 0.010 |
Why?
|
Pulmonary Alveoli | 1 | 2004 | 665 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13425 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 13499 | 0.010 |
Why?
|
Radiology Department, Hospital | 1 | 2004 | 409 | 0.010 |
Why?
|
Age Distribution | 1 | 2006 | 2877 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17626 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 16027 | 0.010 |
Why?
|
Fluorouracil | 1 | 2005 | 1655 | 0.010 |
Why?
|
Glioma | 1 | 2015 | 3526 | 0.010 |
Why?
|
Reference Values | 1 | 2006 | 4941 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40267 | 0.010 |
Why?
|
Trachea | 1 | 2005 | 1095 | 0.010 |
Why?
|
User-Computer Interface | 1 | 2005 | 1397 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2006 | 1973 | 0.010 |
Why?
|
Gestational Age | 1 | 2006 | 3615 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2005 | 3553 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2016 | 6566 | 0.010 |
Why?
|
Child | 1 | 2023 | 80894 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 10377 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26373 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 22355 | 0.010 |
Why?
|